Insider Selling: RAPT Therapeutics (NASDAQ:RAPT) Insider Sells $80,400.00 in Stock

RAPT Therapeutics (NASDAQ:RAPT) insider William Ho sold 2,000 shares of RAPT Therapeutics stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $40.20, for a total transaction of $80,400.00. Following the transaction, the insider now owns 66,058 shares of the company’s stock, valued at $2,655,531.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

William Ho also recently made the following trade(s):

  • On Thursday, October 15th, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $35.76, for a total transaction of $35,760.00.
  • On Thursday, October 1st, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $31.18, for a total transaction of $31,180.00.
  • On Tuesday, September 15th, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $36.14, for a total transaction of $36,140.00.
  • On Tuesday, September 1st, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $26.24, for a total transaction of $26,240.00.
  • On Monday, August 17th, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $24.76, for a total transaction of $24,760.00.
  • On Monday, August 3rd, William Ho sold 1,000 shares of RAPT Therapeutics stock. The shares were sold at an average price of $21.54, for a total transaction of $21,540.00.

Shares of RAPT stock opened at $40.87 on Friday. The firm’s 50-day simple moving average is $32.90 and its two-hundred day simple moving average is $24.30. RAPT Therapeutics has a 52 week low of $10.52 and a 52 week high of $51.21. The firm has a market cap of $1.00 billion and a price-to-earnings ratio of -2.85.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.07. The business had revenue of $1.28 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, analysts expect that RAPT Therapeutics will post -2.12 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC bought a new stake in shares of RAPT Therapeutics in the second quarter valued at approximately $1,647,000. Nuveen Asset Management LLC bought a new stake in shares of RAPT Therapeutics in the second quarter valued at approximately $1,393,000. Charles Schwab Investment Management Inc. raised its position in shares of RAPT Therapeutics by 74.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 51,756 shares of the company’s stock valued at $1,502,000 after purchasing an additional 22,124 shares during the period. Jane Street Group LLC bought a new stake in shares of RAPT Therapeutics in the second quarter valued at approximately $285,000. Finally, Bank of America Corp DE raised its position in shares of RAPT Therapeutics by 3,870.5% in the second quarter. Bank of America Corp DE now owns 22,870 shares of the company’s stock valued at $663,000 after purchasing an additional 22,294 shares during the period. 58.04% of the stock is currently owned by institutional investors.

A number of research analysts recently weighed in on RAPT shares. HC Wainwright raised their price target on shares of RAPT Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Zacks Investment Research lowered shares of RAPT Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 15th. Cantor Fitzgerald lifted their price objective on shares of RAPT Therapeutics from $37.00 to $51.00 and gave the stock an “overweight” rating in a research report on Monday, July 27th. BidaskClub raised shares of RAPT Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price objective on shares of RAPT Therapeutics from $33.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $39.86.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases.

Further Reading: Stochastic Momentum Index (SMI)

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.